Atherosclerosis Research Unit and Department of Medicine, Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Atherosclerosis. 2010 Dec;213(2):449-57. doi: 10.1016/j.atherosclerosis.2010.09.030. Epub 2010 Oct 27.
We recently described anti-atherogenic properties of the dual domain peptide Ac-hE18A-NH(2) derived by covalently linking the heparin binding domain 141-150 of apoE to 18A, a class A amphipathic helical peptide. In this paper we have compared the properties of Ac-hE18A-NH(2) with the non-heparin binding 151-160 region of apoE linked to 18A (Ac-nhE18A-NH(2)).
Both peptides were highly helical in solution and in association with lipids. Ac-hE18A-NH(2) and not Ac-nhE18A-NH(2) enhanced uptake of low density lipoprotein (LDL) in HepG2 cells. While Ac-hE18A-NH(2) retarded the electrophoretic mobility of LDL, Ac-nhE18A-NH(2) slightly enhanced mobility. Ac-hE18A-NH(2) reduced monocyte association with endothelial cells, while Ac-nhE18A-NH(2) increased it. Ac-hE18A-NH(2) also reduced lipid hydroperoxide content of LDL while Ac-nhE18A-NH(2) increased it. A single administration of Ac-hE18A-NH(2) (100 μg/mouse) into apoE null mice dramatically reduced cholesterol (from 600 mg/dL to 180 mg/dL at 5 min and to 60 mg/dL at 5h) while Ac-nhE18A-NH(2) had no effect. Administration (100 μg/mouse/day, three days a week) into apoE null mice for six weeks showed Ac-hE18A-NH(2) group having a moderate aortic sinus lesion reduction compared with the control group (-15.1%), while the Ac-nhE18A-NH(2) administered group had increased lesion area (+33.0% vs controls and 36.1% vs Ac-hE18A-NH(2)). Plasma from mice administered Ac-hE18A-NH(2) for six weeks showed a significant reduction in plasma cholesterol and triglyceride levels and increase in paraoxonase-1 (PON-1) activity compared to controls, while Ac-nhE18A-NH(2) caused no change in plasma cholesterol and decreased PON-1 activity.
It is proposed that Ac-hE18A-NH(2) reduced lesion progression in apoE null mice due to its anti-inflammatory and lipoprotein clearing properties, while Ac-nhE18A-NH(2) exhibited pro-atherogenic effects.
我们最近描述了由共价连接载脂蛋白 E (apoE) 的肝素结合域 141-150 与 A 类两亲性螺旋肽 18A 衍生的双域肽 Ac-hE18A-NH(2) 的抗动脉粥样硬化特性。在本文中,我们比较了 Ac-hE18A-NH(2) 与连接到 18A 的 apoE 的非肝素结合 151-160 区域 (Ac-nhE18A-NH(2)) 的特性。
两种肽在溶液中和与脂质结合时均具有高度的螺旋性。Ac-hE18A-NH(2) 而非 Ac-nhE18A-NH(2) 增强了 HepG2 细胞对低密度脂蛋白 (LDL) 的摄取。虽然 Ac-hE18A-NH(2) 延缓了 LDL 的电泳迁移率,但 Ac-nhE18A-NH(2) 则略微增强了迁移率。Ac-hE18A-NH(2) 减少了单核细胞与内皮细胞的结合,而 Ac-nhE18A-NH(2) 则增加了结合。Ac-hE18A-NH(2) 还降低了 LDL 中脂质氢过氧化物的含量,而 Ac-nhE18A-NH(2) 则增加了含量。单次给予 apoE 缺失小鼠 100 μg/只 Ac-hE18A-NH(2),可在 5 分钟内将胆固醇从 600 mg/dL 降至 180 mg/dL,5 小时后降至 60 mg/dL,而 Ac-nhE18A-NH(2) 则无此作用。在 apoE 缺失小鼠中每周三次给予 100 μg/只 Ac-hE18A-NH(2),6 周后 Ac-hE18A-NH(2) 组主动脉窦病变面积较对照组减少 15.1%,而 Ac-nhE18A-NH(2) 组病变面积增加 36.1%(与对照组相比增加 33.0%,与 Ac-hE18A-NH(2) 相比增加 36.1%)。与对照组相比,连续 6 周给予 Ac-hE18A-NH(2) 的小鼠血浆胆固醇和甘油三酯水平显著降低,对氧磷酶-1 (PON-1) 活性增加,而 Ac-nhE18A-NH(2) 对血浆胆固醇无影响,且降低了 PON-1 活性。
我们提出,Ac-hE18A-NH(2) 降低了 apoE 缺失小鼠的病变进展,这是由于其抗炎和脂蛋白清除特性,而 Ac-nhE18A-NH(2) 则表现出促动脉粥样硬化作用。